Palatin Technologies, Inc. (PTN)
PTN moved a median of -0.54% 30 minutes after news, and -0.41% by the close. How PTN actually reacts to news — the realized, point-in-time move the market made, measured across 177 labeled events over the last three years with zero look-ahead.
PTN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 34% | 152 |
| 30-min | -0.54% | 45% | 165 |
| 60-min | -0.49% | 45% | 166 |
| to close | -0.41% | 40% | 167 |
| Middle 50% of PTN reactions | -2.61% to +1.93% |
|---|---|
| Median reaction (30-min) | -0.54% |
| Measured reactions | 177 |
Half of all Palatin Technologies, Inc. news events land between -2.61% and +1.93% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when PTN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to PTN's baseline. Nothing else.
Recent PTN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 10-K PALATIN TECHNOLOGIES For: Jun 30 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | -4.40% | |
| Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update | Press release | PR Newswire | -3.75% | -2.84% | |
| Form 8-K PALATIN TECHNOLOGIES For: Jul 28 | SEC filing · Form 8-K | SEC EDGAR | — | +7.16% | |
| Form DEF 14A PALATIN TECHNOLOGIES For: Jun 25 | SEC filing · Form DEF | SEC EDGAR | +0.00% | +13.49% | |
| Form 25 PALATIN TECHNOLOGIES | SEC filing · Form 25 | SEC EDGAR | +3.82% | +1.96% | |
| Form 8-A12B PALATIN TECHNOLOGIES | SEC filing · Form 8-A12B | SEC EDGAR | +3.82% | +1.96% | |
| Form CERT PALATIN TECHNOLOGIES | SEC filing · Form CERT | SEC EDGAR | +3.82% | +1.96% | |
| Form 8-K PALATIN TECHNOLOGIES For: May 18 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -3.06% | |
| Palatin to Begin Trading on Nasdaq Stock Exchange | Press release | PR Newswire | +0.00% | -3.06% | |
| Form 10-Q PALATIN TECHNOLOGIES For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -11.89% | |
| Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update | Press release | PR Newswire | +1.06% | -11.97% | |
| Form 10-Q PALATIN TECHNOLOGIES For: Dec 31 | SEC filing · Form 10-Q | SEC EDGAR | — | +9.12% | |
| Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update | Press release | PR Newswire | +3.00% | +12.40% | |
| Form 8-K/A PALATIN TECHNOLOGIES For: Jul 25 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -6.91% | |
| Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update | Press release | PR Newswire | -6.54% | — | |
| Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option | Press release | PR Newswire | +2.96% | +20.92% | |
| Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity | Press release | PR Newswire | — | — | |
| Palatin Announces 1-for-50 Reverse Stock Split | Press release | PR Newswire | — | — | |
| Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update | Press release | PR Newswire | — | — | |
| Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025 | Press release | PR Newswire | — | — | |
| Form 8-K PALATIN TECHNOLOGIES For: May 07 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025 | Press release | PR Newswire | — | — | |
| Palatin Technologies Announces Closing of Reduced Public Offering | Press release | PR Newswire | — | — | |
| Form EFFECT PALATIN TECHNOLOGIES | SEC filing · Form EFFECT | SEC EDGAR | -13.79% | -8.64% | |
| Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice | Press release | PR Newswire | -13.79% | -8.64% | |
| Palatin Technologies Announces Pricing of up to $23 Million Public Offering | Press release | PR Newswire | -13.79% | -8.64% | |
| Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice | Press release | PR Newswire | — | — | |
| Form S-1/A PALATIN TECHNOLOGIES | SEC filing · Form S-1 | SEC EDGAR | -1.49% | -16.06% | |
| Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy | Press release | PR Newswire | -1.49% | -16.06% | |
| Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease | Press release | PR Newswire | -1.35% | -4.65% | |
| Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide | Press release | PR Newswire | -8.73% | -12.70% | |
| Palatin Appeals NYSE American Notice of Delisting | Press release | PR Newswire | -13.48% | -9.33% | |
| Form 8-K PALATIN TECHNOLOGIES For: Apr 10 | SEC filing · Form 8-K | SEC EDGAR | -3.37% | -45.00% | |
| Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal | Press release | PR Newswire | -3.37% | -45.00% | |
| Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting | Press release | PR Newswire | -3.24% | -15.54% | |
| Form RW PALATIN TECHNOLOGIES | SEC filing · Form RW | SEC EDGAR | -1.22% | -2.00% | |
| Form RW WD PALATIN TECHNOLOGIES | SEC filing · Form RW | SEC EDGAR | -9.71% | -1.96% | |
| Form 8-K PALATIN TECHNOLOGIES For: Mar 28 | SEC filing · Form 8-K | SEC EDGAR | -11.93% | -10.73% | |
| Form S-1 PALATIN TECHNOLOGIES | SEC filing · Form S-1 | SEC EDGAR | -1.77% | -12.36% | |
| Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study | Press release | PR Newswire | -11.93% | -10.73% | |
| Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177 | Press release | PR Newswire | -7.34% | -2.63% | |
| Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency | Press release | PR Newswire | -2.99% | -2.40% | |
| Form 10-Q PALATIN TECHNOLOGIES For: Dec 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.98% | +3.92% | |
| Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update | Press release | PR Newswire | +0.98% | +3.92% | |
| Form 8-K PALATIN TECHNOLOGIES For: Feb 11 | SEC filing · Form 8-K | SEC EDGAR | -2.68% | +6.97% | |
| Form 8-K PALATIN TECHNOLOGIES For: Feb 06 | SEC filing · Form 8-K | SEC EDGAR | +2.74% | +8.80% | |
| Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025 | Press release | PR Newswire | +2.74% | +8.80% | |
| Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement | Press release | PR Newswire | +3.92% | +2.94% | |
| Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide | Press release | PR Newswire | +3.77% | +12.50% | |
| Palatin Provides Update on Anticipated 2025 Corporate Milestones | Press release | PR Newswire | -0.61% | -3.28% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the PTN section they belong to.
Where else PTN is measured.
PTN earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Cardax, Inc. (CDXI) | 177 | 0.00% | 13% |
| NRC Health (NRC) | 177 | -0.16% | 38% |
| Rafael Holdings, Inc. Class B (RFL) | 176 | 0.00% | 43% |
| Strata Skin Sciences, Inc. (SSKN) | 176 | 0.00% | 39% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Palatin Technologies, Inc.'s median reaction calculated?
Every labeled PTN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 177 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 45% of PTN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does PTN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.